OEM medical device manufacturing underpins a substantial portion of the devices sold under distributor or health system brand names rather than the name of the company that actually designed and produced them. Original equipment manufacturing arrangements let companies without in-house production capability offer a device portfolio by partnering with an established manufacturer, while private labeling refers specifically to selling that manufactured device under a different brand. For distributors and health systems considering this model — or manufacturers considering offering it — understanding how these partnerships are typically structured helps set realistic expectations from the outset.
How Is an OEM Partnership Typically Structured?
An OEM partnership usually begins with a specification and feasibility discussion, where the commissioning company defines its target device characteristics, intended market, and branding requirements, and the manufacturer assesses whether an existing platform can be adapted or a new design is required. This is followed by design transfer — converting requirements into manufacturing documentation, validated processes, and quality records — and then production, quality release, and shipment under the agreed branding. Throughout this process, the manufacturer typically retains responsibility for the underlying technical file, design history, and regulatory conformity documentation, even though the commissioning company's name appears on the finished product.
What Distinguishes Private Label From Full Custom Development?
Private labeling generally refers to relabeling an existing manufacturer platform with minimal design changes, which tends to be faster and less costly than full custom development, where a device is designed from the ground up to a commissioning company's unique specifications. Full custom development requires more extensive design control documentation, verification and validation activity, and typically a longer timeline before market entry, but it allows for differentiated device characteristics that a private-labeled existing platform cannot offer. Companies evaluating this choice weigh time to market and cost against the strategic value of a differentiated product versus a rebranded existing design.
Why Does Regulatory Ownership Matter in These Arrangements?
Regardless of whose brand appears on a device, the entity responsible for the technical file, European market authorization under the applicable European medical device regulations (for devices intended for the European market), and post-market surveillance must be clearly defined in the OEM agreement. In many arrangements, the original manufacturer retains regulatory responsibility and quality system ownership, with the commissioning company responsible for its own labeling, marketing claims, and distribution compliance. Ambiguity here creates risk for both parties, so a clearly documented regulatory responsibility matrix is a standard part of any well-structured OEM agreement, alongside the manufacturer's internationally recognized quality management standards-certified quality management system underpinning the whole relationship.
How Does INVAMED Approach OEM and Portfolio Manufacturing?
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Is private labeling faster than fully custom device development?
Generally, yes. Private labeling an existing manufacturer platform with minimal modifications typically requires less design verification and validation work than developing a device from a blank specification, which shortens the path to market compared with full custom development.